Venatorx and Roche team up to take on 'superbugs' with new class of antibiotics
Venatorx Pharmaceuticals entered into a research collaboration and license agreement with Roche on Monday to develop a new class of antibiotics that address the increasing threat of "superbugs" that can circumvent existing treatments.
Financial terms of the partnership are being kept confidential.
Under the terms of the collaboration, Malvern-based Venatorx and Roche, a Swiss pharmaceutical and diagnostics company, will work together to discover, characterize and develop new small molecule inhibitors…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: John George Source Type: news
More News: Biotechnology | Health Management | Infectious Diseases | Partnerships | Superbugs | Switzerland Health